General
Preferred name
DIQUAFOSOL
Synonyms
Diquas ()
DIQUAFOSOL TETRASODIUM ()
INS-365 ()
Dicuafosol ()
DIQUAFOSOL TETRASODIUM SALT ()
DIQUAFOSOL SODIUM ()
INS365 ()
INS 365 ()
DE-089 ()
KPY-998 ()
Diquafosol (sodium salt) ()
P&D ID
PD050276
CAS
59985-21-6
211427-08-6
Tags
available
drug candidate
drug
Approved by
PMDA
First approval
2010
Drug indication
Dry eye disease
Drug Status
experimental
approved
investigational
Max Phase
3.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
The USAN specifies the tetrasodium salt formulation.
(GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
16
Cayman Chemical Bioactives
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Drug Repurposing Hub
DrugBank
DrugCentral
DrugCentral Approved Drugs
DrugMAP
EU-OPENSCREEN Bioactive Compound Library
EUbOPEN Chemogenomics Library
Guide to Pharmacology
Natural product-based probes and drugs
Selleckchem Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
56
Molecular Weight
789.99
Hydrogen Bond Acceptors
21
Hydrogen Bond Donors
10
Rotatable Bonds
14
Ring Count
4
Aromatic Ring Count
2
cLogP
-4.19
TPSA
404.45
Fraction CSP3
0.56
Chiral centers
12.0
Largest ring
6.0
QED
0.08
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
MOA
purinergic receptor activator
Biosynthetic Origin
Nucleoside
Therapeutic Indication
Dry Eye Syndrome
Target
P2 Receptor
Recommended Cell Concentration
None
Source data